Literature DB >> 2541199

Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage.

M S O'Dorisio1, B T Shannon, D J Fleshman, L B Campolito.   

Abstract

Specific, high affinity receptors for vasoactive intestinal peptide (VIP) have been identified on a human pre-B cell line, Nalm 6, and on a human plasma cell line, Dakiki. The single class of high affinity sites exhibited a KD of 12.6 +/- 2.9 nM for VIP in Nalm 6 cells and 9.1 +/- 2.7 nM in Dakiki plasma cells. The homologous peptides, peptide histidine methionine (PHM), growth hormone releasing factor (GHRF), and secretin were all less effective than VIP in competitively inhibiting binding of 125I-VIP to Nalm 6 and Dakiki plasma membranes. The putative receptor was characterized as a 47-kDa protein using covalent cross-linking techniques and VIP stimulated adenylate cyclase in pre-B cells. Human lymphocytes of B cell lineage thus appear to express functional VIP receptors homologous to the receptor identified in T lymphoblasts, brain, pituitary, and intestine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541199

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells.

Authors:  C Ishioka; A Yoshida; H Kimata; H Mikawa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

2.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

3.  Cloning and expression of the human vasoactive intestinal peptide receptor.

Authors:  S P Sreedharan; A Robichon; K E Peterson; E J Goetzl
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  The SKW 6.4 line of human B lymphocytes specifically binds and responds to vasoactive intestinal peptide.

Authors:  P P Cheng; S P Sreedharan; J L Kishiyama; E J Goetzl
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

Review 5.  Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.

Authors:  Dongmei Wu; Dongwon Lee; Yong Kiel Sung
Journal:  Respir Res       Date:  2011-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.